Randomized Controlled Trial
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 6, 2021; 9(25): 7417-7432
Published online Sep 6, 2021. doi: 10.12998/wjcc.v9.i25.7417
Clinical effectiveness of adding probiotics to a low FODMAP diet: Randomized double-blind placebo-controlled study
Beril Turan, Göksel Bengi, Ruksan Cehreli, Hale Akpınar, Müjde Soytürk
Beril Turan, Department of Internal Medicine, Dokuz Eylül University, Izmir 35000, Turkey
Göksel Bengi, Hale Akpınar, Müjde Soytürk, Department of Gastroenterology, Dokuz Eylul University Izmir, Izmir 35000, Turkey
Ruksan Cehreli, Department of Preventive Oncology, Dokuz Eylül University, Institute of Oncology, İzmir 35000, Turkey
Author contributions: Turan B, Soytürk M and Bengi G contributed equally to this work, designed the research and drafted the manuscript; Soytürk M and Akpınar H provided administrative and technical support; Çehreli R participated in the regulation, follow-up and evaluation of the diets of patients.
Institutional review board statement: The study was reviewed and approved by the Institutional Ethics committee of Dokuz Eylul University Izmir.
Clinical trial registration statement: This study was conducted with the approval of the Clinical Research Ethics Committee of Dokuz Eylul University (approval No. 2017/01-02) and the Medicines and Medical Devices Agency of the Ministry of Health of Turkey (approval No. 67116).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at soyturkmuj@gmail.com. Participants gave informed consent for data sharing.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Müjde Soytürk, MD, Professor, Department of Gastroenterology, Dokuz Eylul University Izmir, İnciraltı Mahallesi, Mithatpaşa Cd. İnciraltı yerleşkesi No. 1606, Izmir 35340, Turkey. soyturkmuj@gmail.com
Received: April 29, 2021
Peer-review started: April 29, 2021
First decision: May 26, 2021
Revised: June 15, 2021
Accepted: July 16, 2021
Article in press: July 16, 2021
Published online: September 6, 2021
Processing time: 123 Days and 20.8 Hours
Core Tip

Core Tip: A low fermentable oligo, di- and monosaccharides and polyols diet significantly relieved irritable bowel syndrome symptoms in all irritable bowel syndrome subtypes in the initial phase; however, adding probiotics to the diet did not make an additional contribution to symptom relief. Further longer term research using different probiotics is needed to examine the efficiency of probiotic supplementation to a low fermentable oligo, di- and monosaccharides and polyols diet in irritable bowel syndrome.